AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by equities researchers at Shore Capital in a research report issued to clients and investors on Friday, ThisIsMoney.Co.Uk reports.
Several other brokerages have also recently issued reports on AZN. Kepler Capital Markets upped their price target on shares of AstraZeneca from GBX 7,700 ($100.61) to GBX 8,000 ($104.53) and gave the company a “buy” rating in a research report on Tuesday, October 29th. Jefferies Financial Group upped their price objective on shares of AstraZeneca from GBX 6,550 ($85.59) to GBX 6,700 ($87.55) and gave the company a “hold” rating in a research note on Tuesday, October 15th. Deutsche Bank reaffirmed a “buy” rating and issued a GBX 8,300 ($108.45) price objective on shares of AstraZeneca in a research note on Thursday. JPMorgan Chase & Co. set a GBX 7,900 ($103.23) price objective on shares of AstraZeneca and gave the company a “buy” rating in a research note on Tuesday, October 29th. Finally, Bank of America reaffirmed a “buy” rating and issued a GBX 8,500 ($111.07) price objective on shares of AstraZeneca in a research note on Tuesday, October 8th. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the company’s stock. AstraZeneca presently has an average rating of “Hold” and a consensus price target of GBX 7,465.67 ($97.55).
AZN stock traded down GBX 10 ($0.13) during trading on Friday, reaching GBX 7,277 ($95.09). 1,564,493 shares of the company were exchanged, compared to its average volume of 2,310,000. The company has a 50-day moving average of GBX 7,153.54 and a two-hundred day moving average of GBX 6,640.56. The company has a market capitalization of $95.47 billion and a price-to-earnings ratio of 45.65. AstraZeneca has a twelve month low of GBX 5,312 ($69.41) and a twelve month high of GBX 8,227.88 ($107.51). The company has a debt-to-equity ratio of 148.59, a current ratio of 0.92 and a quick ratio of 0.70.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: Dividend Achievers
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.